2010-2020年新诊断心房颤动老年人口服抗凝药使用趋势
这项回顾性队列研究利用Optum's Clinformatics Data Mart行政索赔数据,纳入2010年1月1日至2020年12月31日Medicare Advantage计划中65岁及以上、新诊断心房颤动且缺血性卒中风险升高的患者,每年21603至51236例(2010-2020年总计381488例),评估口服抗凝药(OAC)启动率和非依从性趋势。结果显示,12个月内OAC启动率从2010年20.2%(5405/26782)升至2020年32.9%(7111/21603);DOAC使用从1.1%(291/26782)升至30.9%(6678/21603),华法林从19.1%(5114/26782)降至2.0%(436/21603)。高龄(OR 0.98;95%CI 0.98-0.98)、痴呆(OR 0.57;95%CI 0.55-0.58)、衰弱(OR 0.74;95%CI 0.72-0.76)和贫血(OR 0.75;95%CI 0.74-0.77)与OAC启动几率降低相关。研究期间中位覆盖天数比例从77.6%(IQR 41.0%-96.4%)升至90.2%(IQR 57.4%-98.6%),OAC非依从性从52.2%(2290/4389)降至39.0%(3434/8798)。作者认为,自DOAC问世以来OAC启动有所改善但2020年仍不理想,需要额外策略改善所有老年房颤
要点
- 2010-2020年新诊断房颤老年人12个月内OAC启动率从20.2%(5405/26782)升至32.9%(7111/21603),2020年仍不理想。
- DOAC使用从1.1%(291/26782)升至30.9%(6678/21603),华法林从19.1%(5114/26782)降至2.0%(436/21603)。
- 痴呆(OR 0.57;95%CI 0.55-0.58)、衰弱(OR 0.74;95%CI 0.72-0.76)、贫血(OR 0.75;95%CI 0.74-0.77)与OAC启动几率降低相关。
- 中位覆盖天数比例从77.6%(IQR 41.0%-96.4%)升至90.2%(IQR 57.4%-98.6%),OAC非依从性从52.2%(2290/4389)降至39.0%(3434/8798)。
适用人群与场景
- Medicare Advantage计划中65岁及以上、新诊断心房颤动且缺血性卒中风险升高的受益人,数据来自Optum's Clinformatics Data Mart(2010年1月1日至2020年12月31日)。
诊断标准与关键阈值
- OAC非依从性定义为新启动OAC患者中覆盖天数比例<80%。
研究设计与关键结果
- 回顾性队列研究,纳入2010-2020年每年21603至51236例患者(总计381488例),平均(SD)年龄77.2(6.1)至77.4(6.8)岁,女性13871(51.8%)至22901(49.8%)。
- 12个月内OAC启动率从2010年20.2%(5405/26782)升至2020年32.9%(7111/21603)。
- DOAC使用从2010年1.1%(291/26782)升至2020年30.9%(6678/21603),华法林从19.1%(5114/26782)降至2.0%(436/21603)。
- 高龄(OR 0.98;95%CI 0.98-0.98)、痴呆(OR 0.57;95%CI 0.55-0.58)、衰弱(OR 0.74;95%CI 0.72-0.76)和贫血(OR 0.75;95%CI 0.74-0.77)与OAC启动几率降低相关。
- 中位覆盖天数比例从77.6%(IQR 41.0%-96.4%)升至90.2%(IQR 57.4%-98.6%),OAC非依从性从52.2%(2290/4389)降至39.0%(3434/8798)。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,自DOAC问世以来OAC启动有所改善但2020年仍不理想,需要额外策略改善所有老年房颤患者的卒中预防,包括合并痴呆、衰弱和贫血者。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Undertreatment of older adults with atrial fibrillation with anticoagulation therapy is an important practice gap. It has been posited that the availability of direct oral anticoagulants (DOACs) would improve oral anticoagulant (OAC) initiation in older adults with atrial fibrillation given their superior safety profile compared with warfarin.
OBJECTIVES: To systematically examine trends in OAC initiation and nonadherence in older adults with atrial fibrillation and coexisting geriatric conditions.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study uses administrative claims data from Optum's Clinformatics Data Mart from January 1, 2010, to December 31, 2020. Participants included beneficiaries of Medicare Advantage plans aged 65 years and older with atrial fibrillation and elevated risk of ischemic stroke. Data analysis was performed from October 2021 to October 2022.
EXPOSURES: Coexisting dementia, frailty, and anemia.
MAIN OUTCOMES AND MEASURES: The primary outcomes were OAC initiation within 12 months after the first diagnosis of atrial fibrillation per year and nonadherence with OAC per year (defined as <80% of proportion of days covered among patients newly started on OAC in each year).
RESULTS: There were 21 603 to 51 236 patients per year (total for 2010-2020, 381 488 patients) in the OAC-eligible incident AF cohort (mean [SD] age, 77.2 [6.1] to 77.4 [6.8] years; 13 871 [51.8%] to 22 901 [49.8%] women). OAC initiation within 12 months after incident AF increased from 20.2% (5405 of 26 782 patients) in 2010 to 32.9% (7111 of 21 603 patients) in 2020. DOAC uptake increased from 1.1% (291 of 26 782 patients) to 30.9% (6678 of 21 603 patients), and warfarin initiation decreased from 19.1% (5114 of 26 782 patients) to 2.0% (436 of 21 603 patients). Older age (odds ratio [OR], 0.98; 95% CI, 0.98-0.98), dementia (OR, 0.57; 95% CI, 0.55-0.58), frailty (OR, 0.74; 95% CI, 0.72-0.76), and anemia (OR, 0.75; 95% CI, 0.74-0.77) were associated with lower odds of OAC initiation. During the study period, the median (IQR) proportion of days covered increased from 77.6% (41.0%-96.4%) to 90.2% (57.4%-98.6%), and OAC nonadherence decreased from 52.2% (2290 of 4389 patients) to 39.0% (3434 of 8798 patients).
CONCLUSIONS AND RELEVANCE: Since the introduction of DOACs, OAC initiation in older adults with has improved but remained suboptimal in 2020. Additional strategies are needed to improve stroke prophylaxis in all older adults with atrial fibrillation including those with coexisting dementia, frailty, and anemia.
参考来源
- Ko D, Lin KJ, Bessette LG, et al. Trends in Use of Oral Anticoagulants in Older Adults With Newly Diagnosed Atrial Fibrillation, 2010-2020. JAMA Netw Open. 2022. PMID: 36399339. doi:10.1001/jamanetworkopen.2022.42964
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。